Erythropoiesis-stimulating agents in chronic kidney disease: what have we learned in 25 years?

[1]  Yu-Ting Chang,et al.  Seeking for a way to revive erythropoietin production in chronic kidney disease. , 2013, Journal of the Formosan Medical Association = Taiwan yi zhi.

[2]  Shuei-Liong Lin,et al.  Is the renoprotective effect of erythropoietin in chronic kidney disease a myth? , 2013, Journal of the Formosan Medical Association = Taiwan yi zhi.

[3]  I. Macdougall,et al.  Peginesatide for anemia in patients with chronic kidney disease not receiving dialysis. , 2013, The New England journal of medicine.

[4]  I. Macdougall,et al.  Peginesatide in patients with anemia undergoing hemodialysis. , 2013, The New England journal of medicine.

[5]  M. Brookhart,et al.  Changing patterns of anemia management in US hemodialysis patients. , 2012, The American journal of medicine.

[6]  J. Adamson,et al.  Notice , 2012, Kidney International Supplements.

[7]  L. Rostaing,et al.  Correction of postkidney transplant anemia reduces progression of allograft nephropathy. , 2012, Journal of the American Society of Nephrology : JASN.

[8]  A. Kliger,et al.  Erythropoietic stimulating agents and quality of a patient's life: individualizing anemia treatment. , 2012, Clinical journal of the American Society of Nephrology : CJASN.

[9]  Yihai Cao,et al.  PDGF-BB modulates hematopoiesis and tumor angiogenesis by inducing erythropoietin production in stromal cells , 2011, Nature Medicine.

[10]  Keng T Woo,et al.  KDIGO clinical practice guidelines for bisphosphonate treatment in chronic kidney disease. , 2011, Kidney international.

[11]  Yunfei Xu,et al.  Erythropoietin Increases Expression and Function of Transient Receptor Potential Canonical 5 Channels , 2011, Hypertension.

[12]  A. Xenocostas,et al.  The Role of Erythropoietin and Erythropoiesis-Stimulating Agents in Tumor Progression , 2011, Clinical Cancer Research.

[13]  M. Gassmann,et al.  Erythropoietic and non‐erythropoietic functions of erythropoietin in mouse models , 2011, The Journal of physiology.

[14]  R. Fluck,et al.  Naturally occurring higher hemoglobin concentration does not increase mortality among hemodialysis patients. , 2011, Journal of the American Society of Nephrology : JASN.

[15]  R. Schmieder,et al.  Inhibition of prolyl hydroxylases increases erythropoietin production in ESRD. , 2010, Journal of the American Society of Nephrology : JASN.

[16]  M. Somerfield,et al.  American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. , 2010, Blood.

[17]  M. Somerfield,et al.  American society of clinical oncology/american society of hematology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. , 2010, Journal of oncology practice.

[18]  H. Uno,et al.  Erythropoietic response and outcomes in kidney disease and type 2 diabetes. , 2010, The New England journal of medicine.

[19]  D. Goldsmith.  2009: a requiem for rHuEPOs--but should we nail down the coffin in 2010? , 2010, Clinical journal of the American Society of Nephrology : CJASN.

[20]  D. Tarng,et al.  Bone marrow iron in CKD: correlation with functional iron deficiency. , 2010, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[21]  V. de Waard,et al.  Erythropoietin accelerates smooth muscle cell-rich vascular lesion formation in mice through endothelial cell activation involving enhanced PDGF-BB release. , 2010, Blood.

[22]  I. Macdougall,et al.  A peptide-based erythropoietin-receptor agonist for pure red-cell aplasia. , 2009, The New England journal of medicine.

[23]  S. Solomon,et al.  A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. , 2009, The New England journal of medicine.

[24]  G. Heinze,et al.  Mortality in renal transplant recipients given erythropoietins to increase haemoglobin concentration: cohort study , 2009, BMJ : British Medical Journal.

[25]  J. Zaritsky,et al.  Hepcidin for clinicians. , 2009, Clinical journal of the American Society of Nephrology : CJASN.

[26]  M. Zwahlen,et al.  Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials , 2009, The Lancet.

[27]  S. Greenland,et al.  Erythropoietin, iron depletion, and relative thrombocytosis: a possible explanation for hemoglobin-survival paradox in hemodialysis. , 2008, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[28]  R. Califf,et al.  Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes. , 2008, Kidney international.

[29]  In‐San Kim,et al.  Erythropoietin decreases renal fibrosis in mice with ureteral obstruction: role of inhibiting TGF-beta-induced epithelial-to-mesenchymal transition. , 2007, Journal of the American Society of Nephrology : JASN.

[30]  Ajay K. Singh,et al.  Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: results of the Dialysis Patients' Response to IV Iron with Elevated Ferritin (DRIVE) Study. , 2007, Journal of the American Society of Nephrology : JASN.

[31]  H. Burger,et al.  Normalization of hemoglobin level in patients with chronic kidney disease and anemia. , 2006, The New England journal of medicine.

[32]  Huiman Barnhart,et al.  Correction of anemia with epoetin alfa in chronic kidney disease. , 2006, The New England journal of medicine.

[33]  A. Cerami,et al.  Discovering erythropoietin's extra-hematopoietic functions: biology and clinical promise. , 2006, Kidney international.

[34]  Kdoqi Disclaimer,et al.  KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease. , 2006, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[35]  K. Kalantar-Zadeh,et al.  Time-dependent associations between iron and mortality in hemodialysis patients. , 2005, Journal of the American Society of Nephrology : JASN.

[36]  A. Scherhag,et al.  Effects of Optimized Heart Failure Therapy and Anemia Correction with Epoetin β on Left Ventricular Mass in Hemodialysis Patients , 2005, American Journal of Nephrology.

[37]  I. Macdougall,et al.  Pentoxifylline improves hemoglobin levels in patients with erythropoietin-resistant anemia in renal failure. , 2004, Journal of the American Society of Nephrology : JASN.

[38]  Kai-Uwe Eckardt,et al.  Anti-erythropoietin antibodies and pure red cell aplasia. , 2004, Journal of the American Society of Nephrology : JASN.

[39]  Chiu-Ching Huang,et al.  Improved Iron Utilization and Reduced Erythropoietin Resistance by On-Line Hemodiafiltration , 2002, Blood Purification.

[40]  D. Tarng,et al.  Intravenous ascorbic acid as an adjuvant therapy for recombinant erythropoietin in hemodialysis patients with hyperferritinemia. , 1999, Kidney international.

[41]  D. Tarng,et al.  Erythropoietin hyporesponsiveness: from iron deficiency to iron overload. , 1999, Kidney international. Supplement.

[42]  D. Tarng,et al.  A parallel, comparative study of intravenous iron versus intravenous ascorbic acid for erythropoietin-hyporesponsive anaemia in haemodialysis patients with iron overload. , 1998, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[43]  A R Nissenson,et al.  The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. , 1998, The New England journal of medicine.

[44]  R. Peces,et al.  Antibodies against recombinant human erythropoietin in a patient with erythropoietin-resistant anemia. , 1996, The New England journal of medicine.

[45]  E. Friedman,et al.  The intensity of hemodialysis and the response to erythropoietin in patients with end-stage renal disease. , 1996, The New England journal of medicine.

[46]  J. Adamson,et al.  Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter clinical trial. , 1989, Annals of internal medicine.

[47]  J. Adamson,et al.  Treatment of the anemia of progressive renal failure with recombinant human erythropoietin. , 1989, The New England journal of medicine.

[48]  A. Raine.  HYPERTENSION, BLOOD VISCOSITY, AND CARDIOVASCULAR MORBIDITY IN RENAL FAILURE: IMPLICATIONS OF ERYTHROPOIETIN THERAPY , 1988, The Lancet.

[49]  J. Adamson,et al.  Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. , 1987, The New England journal of medicine.

[50]  C. Winearls,et al.  EFFECT OF HUMAN ERYTHROPOIETIN DERIVED FROM RECOMBINANT DNA ON THE ANAEMIA OF PATIENTS MAINTAINED BY CHRONIC HAEMODIALYSIS , 1986, The Lancet.

[51]  C. H. Lin,et al.  Cloning and expression of the human erythropoietin gene. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[52]  E. Goldwasser,et al.  Purification of human erythropoietin. , 1977, The Journal of biological chemistry.

[53]  T. Connor,et al.  Renal handling of calcium and phosphate during mineralocorticoid "escape" in man. , 1972, Kidney international.

[54]  E. Goldwasser,et al.  Role of the Kidney in Erythropoiesis , 1957, Nature.

[55]  Shuei-Liong Lin,et al.  Reply to comment on: Is the renoprotective effect of erythropoietin in chronic kidney disease a myth? , 2014, Journal of the Formosan Medical Association = Taiwan yi zhi.

[56]  W. Winkelmayer.  Against TREATing all patients alike: lessons from an FDA Advisory Committee Meeting. , 2011, Journal of the American Society of Nephrology : JASN.

[57]  M. Gassmann,et al.  Erythropoietic and non‐erythropoietic functions of erythropoietin in mouse models , 2011, The Journal of physiology.

[58]  E. Neilson,et al.  Twenty Years Already , 2010 .